 | |
| Company type | Public company |
|---|---|
| Industry | Pharmaceutical industry |
| Founded | 1995 |
| Headquarters | Oxford |
Key people | Frank Mathias (CEO) |
| Revenue |  £128.8 million (2024)[1] |
| £(39.4) million (2024)[1] | |
| £(48.6) million (2024)[1] | |
| Website | https://oxb.com/ |
Oxford Biomedica (OXB) is a gene and cell therapy company specialising in the development ofgene-based medicines. It is listed on theLondon Stock Exchange and is a constituent of theFTSE 250 Index.[2]
The company was established in 1995 as a spin out from theUniversity of Oxford.[3] It was the subject of aninitial public offering on theAlternative Investment Market in 1996.[4]
In 2018, OXBs gene therapy for Parkinson's disease became the subject of a commercialization deal withAxovant Sciences.[5]
In May 2019, the company announced an investment byNovo Holdings for a stake of 10.1% in OXB, totalling $55 million (USD) to develop its gene therapy technology.[6] The firm had already established collaborations with Sanofi, Novartis and other groups to provide lentiviral vector manufacturing.[7]
In November 2019,Microsoft announced a partnership with OXB to improve the next generation ofcell andgene delivery technology using the cloud andmachine learning, contributing large data sets for analysis via theMicrosoft Azure intelligent cloud platform to develop in-silico models and novel algorithms to help provide long-term and curative treatments for a wide range of diseases.[8]
In December 2019, the company announced that it has extended its commercial supply agreement with Novartis for the manufacture of lentiviral vectors for theNovartisCAR-T portfolio including five lentiviral vectors for CAR-T products, which builds on the existing three-year commercial supply agreement signed by the parties in July 2017.[9]
In April 2020, OXB announced that the company had joined a Consortium led by the Jenner Institute, Oxford University, to develop and manufacture a vaccine for COVID-19:ChAdOx1 nCov-19.[10] This is one of the vaccines currently being deployed under a conditional authorisation.[11][12]
In September 2023, it was announced OXB had acquired theIllkirch-Graffenstaden-headquartered,viral vectors drug product manufacturing services company, ABL Europe from theMérieux Institute.[13]
